Clinical Trial Search

Primary: Number of Participants With Composite Safety Endpoint of the Occurrence of Serious Adverse Events (SAEs) or Division of AIDS (DAIDS) Grade 3 and 4 Signs and Symptoms…

Primary: Incidence of Confirmed Herpes-Zoster — 32.889; 91.883 Number of cases per 1000 person years

Primary: Percentage of Participants Showing a Vaccine Response for Anti-glycoprotein E (gE) — 85.7; 7.8 Percentage of participants

Primary: Magnitude of Varicella-Zoster Virus (VZV) DNAemia — NA; NA; NA; NA DNA copies per/mL

Primary: Change in Cell Mediated Immunity — 33; 33; 33; 50 cells per million — p=0.16

Primary: Answers to Survey Questions — 89; 71.2; 98; 74 Percentage of responders

Primary: Incidence Rate of Confirmed Herpes Zoster (HZ) Cases — 0.0; 8.2 Cases per 1000 person-years — p=<0.0001

Primary: Number of Participants Who Received the Herpes Zoster Vaccine — 500; 2089 Participants

Primary: Vaccine-related Serious Adverse Experiences (SAEs) for 28 Days Postvaccination — 0; 0; 100; 101 Participants

Primary: Number of Subjects With Confirmed Herpes Zoster (HZ) Episode — 49; 135 Participants — p=<0.0001

Primary: Frequency of Glycoprotein E (gE)-Specific Cluster of Differentiation (CD4) T-cells Expressing at Least Two Different Activation Markers — 1801.23; 1722.83; 1778.48…

Primary: Number of Vaccine Responders for Anti-gE Antibodies as Determined by ELISA — 74; 26; 26; 22 Participants

Primary: The Percentage of Participants Achieving Cessation of New Lesion Formation by Day 4 of Study Treatment — 69.6; 81.1; 75.1 percentage of Participants — p=0.00000241

Primary: Evaluation of Herpes Zoster (HZ) and Postherpetic Neuralgia (PHN) Related Direct Medical Costs by Drugs Prescribed. — 10; 1; 3; 0 Participants

Primary: Change of Pain Measured by VAS — 5.8; 2.2; 0.6; 1.2 pain intensity

Primary: Incidence of Confirmed Herpes-Zoster — 6.737; 18.457 Number of cases per 1000 person years

Primary: Number of Subjects With Any and Grade 3 Solicited Local Symptoms — 25; 19; 22; 4 Participants

Primary: Incidence of Confirmed Herpes Zoster (HZ) Cases by Vaccination Group — 1.994; 6.596 number of HZ cases/1000 person-years — p=<.001

Primary: Number of Participants With the First Occurrence of New or Worsening Stromal Keratitis Without Ulceration (SK), Endothelial Keratitis (EK), Iritis (IR), Dendriform…

Primary: Number of Participants With Innate Immunity Signatures That Correlate With the T Cell Adaptive Immunity Responses After ZOSTAVAX — 44; 33 participants

Primary: Geometric Mean Fold Rise (GMFR) From Day 1 in Varicella Zoster Virus (VZV) Antibody — 2.8 Ratio

Primary: Number of Subjects With Anti-gE Antibody Concentrations Equal to or Above the Cut-off Value — 210; 210; 202 Subjects

Primary: GMFR (Geometric Mean Fold Rise ) in Varicella Zoster Virus (VZV) Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Immunoglobulin G (IgG) Levels From Baseline at…

Primary: Overall Incidence Rate of Herpes Zoster (HZ) Cases, by Age and Gender — 5.19; 6.29; 5.00; 9.19 Number of HZ cases/1000 person-years

Primary: Number of Participants Experiencing Incidence of Nephrotoxicity, Defined as a Serum Creatinine ≥ 2 Times the Patient's Baseline — 2; 3 participants

Primary: Change in Innate Immune Signatures Post-vaccine Dose — 1.6801; 2.096; -0.5609; -1.1284 Normalized Enrichment Score (NES)

Primary: Percentage of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE) in Co-Ad Group — 99.1 Percentage of subjects

Primary: Number of Subjects With Confirmed Herpes Zoster (HZ) Cases — 3; 2; 1; 6 Participants — p=<0.0001

Primary: Incidence Rate of Confirmed Herpes Zoster (HZ) Cases — 0.0; 4.1 Cases per 1000 person-years

Primary: Number of Subjects With Any Episodes of Herpes Zoster (HZ) — 17; 6; 23; 169 Participants — p=<0.0001